Cached score snapshot

US.IDXX · Idexx Laboratories

110分制 62.3/110;5D動能v2 9/50;排序分 71.3/160 · Incomplete inputs

Ranking score 71.3/160
Main score 62.3/110
5D momentum v2 9/50
Rank #137
Setup grade D 35.4

Score breakdown

觀望

Medium twelvedata

Score and price trend

D 35.4 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 05-12 08-05 08-21 09-03 09-17 $505.71$598.82$691.93 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.557 · anchors 120 -0.28% -2.47% / +2.61% 48.8% 8.8% Actual -0.57% · vs median -0.29% · inside 25-75 band
30D observation +8.27% +4.50% / +12.16% 92.5% 1.3% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 -0.01% -2.33% / +2.78% 49.4% 5% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-05-12 → 2026-09-17 · 229 archived points · 2 Improving turn signal · 8 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 71.3
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 62.3/110 (觀望)
5D momentum v2 9/50 (弱)
Score with momentum v2 71.3/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分,但以下輸入仍不完整;缺失維度以 0 分處理,請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 562.902
ma50 559.2538
close 590
prevClose 584.78
avgVolume20 656839
volumeRatio 0.97
changePercent 0.89

Metrics snapshot

close 590
volume 639379
changePercent 0.89

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 62.3/110
Main rating 觀望
5D momentum v2 9/50
Score with momentum v2 71.3/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 4.6/5 · 優秀

Dimension score 4.6/5
Dimension grade 優秀

Sub-items

pbPoints 0.2
pePoints 0.2
epsPoints 0.75
roePoints 0.75
debtPoints 0.5
marginPoints 0.75
turnoverUsdM 377.2336
volumePoints 0.5
revenuePoints 0.4
dividendPoints 0
marketCapPoints 0.5

資金流 — 12.4/20 · 一般

Dimension score 12.4/20
Dimension grade 一般

Sub-items

cmfPoints 0.8
mfiPoints 1.6
obvPoints 4
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.IDXX
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 5.8/15 · 較差

Dimension score 5.8/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 3

details

qqq

ma20 700.462
ma50 714.6952
name QQQ
close 714.62
points 1

spy

ma20 749.2555
ma50 746.7324
name SPY
close 768.53
points 2
source twelvedata+fred
atrPct 3.2884
atrPoints 2
cciPoints 0.8
vixPoints 0
marketTrendPoints 3

催化劑 — 6/20 · 較差

Dimension score 6/20
Dimension grade 較差

Sub-items

catalyst

score 6

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 1
catalystPoints 6

風險管理 — 6.7/10 · 一般

Dimension score 6.7/10
Dimension grade 一般

Sub-items

position

score 1.3

details

atrPct 3.2884
turnoverUsdM 377.2336
liquidityPoints 0.6
volatilityPoints 0.7
rrPoints 1.6

stopLevels

symbol US.IDXX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 551.1964

strength_details

ma_score 2
atr_score 1
rsi_score 3
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1.5
stop_loss_percent 6.6
take_profit_price 649.7575
target_multiplier 2.2
technical_strength 2.1
take_profit_percent 10.1
positionPoints 1.3
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.5357
stopLossPercent 6.5769
diversificationPoints 2

技術信號 — 20.8/30 · 一般

Dimension score 20.8/30
Dimension grade 一般

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 0.9
macdPoints 4

vcpPayload

vcp_pass false
vcp_score 0.9
vcp_reason 站上MA50;升放量(近10日2日);Ready=N;Confirm=Y

vcp_metrics

up_days 7
vol_ref 697903.3333
down_days 2
vcp_ready false
above_ma50 true
avg_vol_10 716190
avg_vol_20 674515
avg_vol_30 697903.3333
range_pct_10 0.1522
range_pct_20 0.1522
range_pct_30 0.179
up_expand_ok true
lookback_used 59
near_20d_high true
contraction_ok false
down_shrink_ok false
up_expand_days 2
breakout_20d_ok false
vol_ratio_10_30 1.0262
dist_to_20d_high 0.0547
down_shrink_days 1
breakout_level_20d 624.15
vcp_breakout_confirm true
contraction_ratio_10_30 0.8503
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 2.4
shortRsiPoints 1
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 0.8

情緒分析 — 6/10 · 一般

Dimension score 6/10
Dimension grade 一般

Sub-items

sentiment

score 6

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 4
sentimentScoreRaw 1.2

sentimentData

raw {"id":141137395,"url":"https://finnhub.io/api/news?id=508ecee4b431fd16e2434a6b8e6ab733a99c95454a2c88c6ea980ae36db4e0de","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.","category":"company","datetime":1786034702,"headline":"Here is Why Growth Investors Should Buy Idexx (IDXX) Now"}, {"id":141115049,"url":"https://finnhub.io/api/news?id=35666a9bb49c4defe08fd7f184a0fdaf5e5299135345edcdfa0af2ae31070cf5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"IDEXX Laboratories Inc (IDXX) delivers 10% revenue growth and raises full-year EPS outlook, driven by innovation and international expansion despite soft US clinical visits.","category":"company","datetime":1785877482,"headline":"IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ..."}, {"id":141111998,"url":"https://finnhub.io/api/news?id=83e1f9fb12f611558ef734564b6fd42e2870b2d019da6072c3946cd0eb8eb275","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.","category":"company","datetime":1785858600,"headline":"IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market"}, {"id":141110272,"url":"https://finnhub.io/api/news?id=df4fe0d5649e29085ff8f5db2463bf2ba5929763aa3afc4e378245e55119c9f5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.","category":"company","datetime":1785850203,"headline":"Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say"}, {"id":141110757,"url":"https://finnhub.io/api/news?id=10d15d5066a10226b8b4f2707dca3e330f79462337105e2a790aa74f16daa661","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"IDXX","summary":"IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDTCompany ParticipantsAndrew Emerson - Executive VP, CFO &...","category":"company","datetime":1785847203,"headline":"IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript"}, {"id":141108859,"url":"https://finnhub.io/api/news?id=e64abee23339868ce4d7fdeb84d6e5cab92de3c3011238b7cc317ca976d4a62e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"Idexx (IDXX) delivered earnings and revenue surprises of +8.10% and +1.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785843602,"headline":"Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates"}, {"id":141107590,"url":"https://finnhub.io/api/news?id=0635386d343671799513e1a251b0499c00d73d358e70668a88cd5cbd3cab1c9d","image":"https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp","source":"ChartMill","related":"IDXX","summary":"IDEXX Laboratories Q2 EPS beats estimates, revenue in line; raises full-year organic growth and margin outlook, shares rise 3.7% premarket.","category":"company","datetime":1785843538,"headline":"IDEXX Laboratories (NASDAQ:IDXX) Shares Rise on Q2 Earnings Beat and Improved Outlook"}, {"id":141107199,"url":"https://finnhub.io/api/news?id=3fa4a1c8b8141c2ebb6d273173d2541b08b83b8dc8869f4c6e1e5382bd4bf23a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"Evaluate the expected performance of Idexx (IDXX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.","category":"company","datetime":1785503704,"headline":"Insights Into Idexx (IDXX) Q2: Wall Street Projections for Key Metrics"}
raw_source {"id":141137395,"url":"https://finnhub.io/api/news?id=508ecee4b431fd16e2434a6b8e6ab733a99c95454a2c88c6ea980ae36db4e0de","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.","category":"company","datetime":1786034702,"headline":"Here is Why Growth Investors Should Buy Idexx (IDXX) Now"}, {"id":141127989,"url":"https://finnhub.io/api/news?id=9ea47d2df35b0a3000496d548d8eb669c74f4e1765fc3d2d1d09adc207567acf","image":"","source":"Benzinga","related":"IDXX","summary":"UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $620 to $670.","category":"company","datetime":1785947269,"headline":"UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670"}, {"id":141127990,"url":"https://finnhub.io/api/news?id=2d8aeb3471d09af00fde5776b03b792f1a86254ca7c38f585d9ec65ec7c33492","image":"","source":"Benzinga","related":"IDXX","summary":"Citigroup analyst Daniel Grosslight maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $650 to $670.","category":"company","datetime":1785941909,"headline":"Citigroup Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670"}, {"id":141116574,"url":"https://finnhub.io/api/news?id=1609d532f3454898719b288eb650c0d0015b7435f5d672dd36fb565cb9b5e16b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"Moby summary of IDEXX Laboratories, Inc.'s Q2 2026 earnings call","category":"company","datetime":1785881732,"headline":"IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary"}, {"id":141115049,"url":"https://finnhub.io/api/news?id=35666a9bb49c4defe08fd7f184a0fdaf5e5299135345edcdfa0af2ae31070cf5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"IDEXX Laboratories Inc (IDXX) delivers 10% revenue growth and raises full-year EPS outlook, driven by innovation and international expansion despite soft US clinical visits.","category":"company","datetime":1785877482,"headline":"IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ..."}, {"id":141111997,"url":"https://finnhub.io/api/news?id=879ec92aa94d2ff93e91544e65d404a03f30dee6a7ec215f202c64407575e671","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing s","category":"company","datetime":1785859468,"headline":"IDEXX Laboratories Q2 Earnings Call Highlights"}, {"id":141111998,"url":"https://finnhub.io/api/news?id=83e1f9fb12f611558ef734564b6fd42e2870b2d019da6072c3946cd0eb8eb275","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.","category":"company","datetime":1785858600,"headline":"IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market"}, {"id":141110272,"url":"https://finnhub.io/api/news?id=df4fe0d5649e29085ff8f5db2463bf2ba5929763aa3afc4e378245e55119c9f5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.","category":"company","datetime":1785850203,"headline":"Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say"}, {"id":141108599,"url":"https://finnhub.io/api/news?id=9e1fcc0db18c7b217918b53e92794d7424423d9adeeac84c7117497a2224b4eb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively trad","category":"company","datetime":1785849279,"headline":"Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Strait of Hormuz Re-Opening Hopes"}, {"id":141110757,"url":"https://finnhub.io/api/news?id=10d15d5066a10226b8b4f2707dca3e330f79462337105e2a790aa74f16daa661","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"IDXX","summary":"IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDTCompany ParticipantsAndrew Emerson - Executive VP, CFO &...","category":"company","datetime":1785847203,"headline":"IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript"}, {"id":141108584,"url":"https://finnhub.io/api/news?id=be360b5ab3037f6e5b84023ad5260321d5a02ff6bbf4cb5616b3d33c11e350aa","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"The 180 MW Phase II portion of the Millers Branch Solar Facility in Haskell County, Texas has achieved commercial operation. The capacity was contracted through Sustainability Roundtable, Inc's Net Zero Consortium for Buyers (NZCB) by Cisco, Juniper Networks (now part of Hewlett Packard Enterprise), Bio-Rad Laboratories, Cadence Design Systems, IDEXX Laboratories, Inc., PTC, and a large healthcare company, which signed an aggregated virtual power purchase agreement (VPPA) with Southern Power Com","category":"company","datetime":1785846600,"headline":"SR Inc Net Zero Consortium for Buyers: Seven-Buyer Aggregation for 180 MW of Millers Branch Solar Now Online"}, {"id":141108858,"url":"https://finnhub.io/api/news?id=7bba2e26b45919de61a82ea0a88d1559c686252b35de4654cfef676d2bac86ec","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"IDEXX Laboratories Inc. (NASDAQ:IDXX) shares rose nearly 4% in pre-market trading after the veterinary diagnostics company reported second-quarter 2026 results that exceeded Wall Street expectations and increased its full-year earnings guidance.","category":"company","datetime":1785845734,"headline":"IDEXX Laboratories Shares Climb After Earnings Beat and Improved Full-Year Outlook"}, {"id":141108859,"url":"https://finnhub.io/api/news?id=e64abee23339868ce4d7fdeb84d6e5cab92de3c3011238b7cc317ca976d4a62e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"Idexx (IDXX) delivered earnings and revenue surprises of +8.10% and +1.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785843602,"headline":"Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates"}, {"id":141110524,"url":"https://finnhub.io/api/news?id=d507772958f2a8a819a520e890396c431b45d6cadd3662cbe5fc9050696b43b5","image":"https://cdn.benzinga.com/files/images/story/2026/08/04/Saint-Petersburg--Russia---June-25--2019.jpg?width=2048&height=1536","source":"Benzinga","related":"IDXX","summary":"IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates.","category":"company","datetime":1785843581,"headline":"Why Is IDEXX Laboratories Stock Gaining Tuesday?"}, {"id":141107590,"url":"https://finnhub.io/api/news?id=0635386d343671799513e1a251b0499c00d73d358e70668a88cd5cbd3cab1c9d","image":"https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp","source":"ChartMill","related":"IDXX","summary":"IDEXX Laboratories Q2 EPS beats estimates, revenue in line; raises full-year organic growth and margin outlook, shares rise 3.7% premarket.","category":"company","datetime":1785843538,"headline":"IDEXX Laboratories (NASDAQ:IDXX) Shares Rise on Q2 Earnings Beat and Improved Outlook"}, {"id":141107879,"url":"https://finnhub.io/api/news?id=ed480ae00c1539e1892006ea492210346c62f6b9a8e81f21bd2104a0bb3d9830","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"WESTBROOK, Maine, August 04, 2026--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results.","category":"company","datetime":1785839400,"headline":"IDEXX Laboratories Announces Second Quarter Results"}, {"id":141110525,"url":"https://finnhub.io/api/news?id=ad9101e6b258fb9df0687c4fd5bfb4b57c4560459a911f54eec7154cb67c7bc3","image":"https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=2048&height=1536","source":"Benzinga","related":"IDXX","summary":"IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below.\nThis transcript is brought to you by","category":"company","datetime":1785836133,"headline":"IDEXX Laboratories Q2 2026 Earnings Call Transcript"}, {"id":141110526,"url":"https://finnhub.io/api/news?id=1ad20007053f9b0a59617bdf1d05c449115862bcff863f1dc1744b563b72aed6","image":"","source":"Benzinga","related":"IDXX","summary":"IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to $4.700 billion-$4.745","category":"company","datetime":1785825085,"headline":"IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est"}, {"id":141110527,"url":"https://finnhub.io/api/news?id=62ef9305ab6ee3d802c53446aecac4ad338233beefe19782bf2a33317cea31b0","image":"","source":"Benzinga","related":"IDXX","summary":"IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $4.27 per share which beat the analyst consensus estimate of $3.96 by 7.83 percent. This is a 17.63 percent increase over earnings of $3.63 per share from","category":"company","datetime":1785825041,"headline":"IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate"}, {"id":141107199,"url":"https://finnhub.io/api/news?id=3fa4a1c8b8141c2ebb6d273173d2541b08b83b8dc8869f4c6e1e5382bd4bf23a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"Evaluate the expected performance of Idexx (IDXX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.","category":"company","datetime":1785503704,"headline":"Insights Into Idexx (IDXX) Q2: Wall Street Projections for Key Metrics"}, {"id":141064002,"url":"https://finnhub.io/api/news?id=78a4d1603a77e856648e6b81ca7e57bd4535b29f68a48b51a09468d5d73cd6f2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"Corporate responsibility report puts IDEXX Laboratories (IDXX) in focus IDEXX Laboratories (IDXX) recently released its 2025 Corporate Responsibility Report, drawing attention to the stock as investors assess how the company’s plans for pet diagnostics, employees, and sustainability fit into its long term outlook. See our latest analysis for IDEXX Laboratories. The recent 6.3% 30 day share price return contrasts with IDEXX Laboratories’ share price being down 15.0% year to date, while the 3...","category":"company","datetime":1785402557,"headline":"Is IDEXX Laboratories (IDXX) Fairly Valued After Its 2025 Corporate Responsibility Report?"}, {"id":141044045,"url":"https://finnhub.io/api/news?id=b1da3556d2d574e870a83df23713073e6a9208be636af8ce22b2f1ae4863e556","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"IDEXX Laboratories (NASDAQ:IDXX) released its 2025 Corporate Responsibility Report, outlining progress across innovation, workforce development, and environmental initiatives that support the company’s long-term growth strategy. Key Investor TakeawaysIDEXX published its 2025 Corporate Responsibility Report, highlighting advances in innovation, employee development, and sustainability.","category":"company","datetime":1785247577,"headline":"IDEXX Releases 2025 Corporate Responsibility Report Highlighting Innovation and Sustainability Progress"}, {"id":141041871,"url":"https://finnhub.io/api/news?id=b2b39e026a9f2b1d33a3361976ee4c82a3961bb0b961ec4983de41dc2a6ac5ee","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"WESTBROOK, Maine, July 28, 2026--IDEXX releases 2025 Corporate Responsibility Report highlighting progress against its goals and commitments.","category":"company","datetime":1785236400,"headline":"IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals"}, {"id":141035335,"url":"https://finnhub.io/api/news?id=5955aa767bb5270fec33b69b0c4c5c70daa999824702bad4a7ec9365aa0a90a6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"Elanco Animal Health (ELAN) seems \"best-positioned name\" into the Q2 print, with IDEXX Laboratories","category":"company","datetime":1785172169,"headline":"Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says"}, {"id":141037509,"url":"https://finnhub.io/api/news?id=24398a18d386daee23962fa28a40282f669fdac74cb88dc12bc606fba6db6311","image":"","source":"Benzinga","related":"IDXX","summary":"UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $640 to $620.","category":"company","datetime":1785161332,"headline":"UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $620"}, {"id":141034163,"url":"https://finnhub.io/api/news?id=7dfbcbf4ac51d4c89fb1a320c9a619e05c9b4623934b10d1328c714f4f1f1c4e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"IDXX Laboratories heads into Q2 earnings with revenue and EPS growth expected, led by CAG diagnostics, VetLab gains and expanding software adoption.","category":"company","datetime":1785157860,"headline":"Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings"}, {"id":141032284,"url":"https://finnhub.io/api/news?id=7dd4d57acaf274b6e3e346093d3355cfad56eb8eb2422b863e70ef234edf607a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Composite “. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]","category":"company","datetime":1785153600,"headline":"IDEXX Laboratories (IDXX) Looks Attractive on Recurring Revenue and High Customer Retention"}, {"id":140952943,"url":"https://finnhub.io/api/news?id=d9e8b333e8a462d43b0b84e3d28b24f605b4595d4a56df8c849f9112e8b797fe","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1056792912/image_1056792912.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"IDXX","summary":"Ron Baron’s BAMCO 13F update: $33.13B portfolio with Tesla top stake (13.39%), major buys/sells, and rebalancing moves—read more now.","category":"company","datetime":1784468597,"headline":"Tracking Ron Baron's BAMCO Portfolio - Q1 2026 Update"}, {"id":140944614,"url":"https://finnhub.io/api/news?id=307e412a7579741a0fddefc62643bfcb67d4a3ac5c44974b5af6ec260e2e65c5","image":"https://image.cnbcfm.com/api/v1/image/108335808-1784189865798-gettyimages-168597290-000023514379_Unapproved.jpeg?v=1784189915&w=1920&h=1080","source":"CNBC","related":"IDXX","summary":"Startups are testing GLP-1 treatments for overweight cats while pet-food giants are leaning into longevity products as owners spend more on animal health.","category":"company","datetime":1784336402,"headline":"Fat cat? Weight-loss drugs may be coming for your overweight pet"}, {"id":140912442,"url":"https://finnhub.io/api/news?id=d213a7bc45e61de090c471914ad23104be342b21d7fdfd1d103000c412ff81b2","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"IDXX","summary":"Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.","category":"company","datetime":1784142301,"headline":"Which S&P500 stocks are moving on Wednesday?"}, {"id":140910529,"url":"https://finnhub.io/api/news?id=17e09f5f6e4cea4cc429b9c6762b4a6aea15f224d1fcabc885c31bb22bc18f3f","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"IDXX","summary":"Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.","category":"company","datetime":1784133300,"headline":"These S&P500 stocks are moving in today's session"}, {"id":140909866,"url":"https://finnhub.io/api/news?id=1f4f929efb2a32e0b32eb27e903fc3db2f1bf483f90bbb2e518c77ea8ed7d823","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"As data centers strain water systems, FIW, PHO, and CGW offer investors ETF-based access to water utilities, infrastructure, and equipment firms, each with distinct fees and concentration.","category":"company","datetime":1784040300,"headline":"These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending"}, {"id":140897029,"url":"https://finnhub.io/api/news?id=de059f2a8fa06678f5cc3ec3105d8f2309e7ab75251bb23b2ed80e39fd10c688","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"ISRG, IDXX and ALC are three AI-driven medical device laggards with strong business momentum and improving earnings estimates for a potential 2H rebound.","category":"company","datetime":1784029020,"headline":"Buy 3 AI-Led Medical Devices Laggards of 1H Set to Gather Pace in 2H"}, {"id":140891433,"url":"https://finnhub.io/api/news?id=0d1b45131aa89d56944dfc353489756ba4f4b458a3280ab510525755ce221788","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"IDEXX Laboratories will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.","category":"company","datetime":1783951251,"headline":"IDEXX Laboratories Earnings Preview: What to Expect"}, {"id":140852386,"url":"https://finnhub.io/api/news?id=73d2e925c78520c16003ce9b14439312d62e875d68f28251208e2f9c1544a395","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.","category":"company","datetime":1783607280,"headline":"Illumina Stock Gains 43.7% in 2026: What's Powering the Rally?"}, {"id":140851088,"url":"https://finnhub.io/api/news?id=9410d1b059637b5b9b027f896f96c5969d2fb0cedd319521c369aa322f8e57b7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"National Veterinary Associates (NVA), a leading pet healthcare services company, today announced the appointment of Laura Tortorella, Chief Executive Officer of AccentCare, and Tina Hunt, PhD, former Executive Vice President of IDEXX Laboratories, to its Board, effective immediately.","category":"company","datetime":1783598400,"headline":"National Veterinary Associates Welcomes Laura Tortorella and Tina Hunt, PhD, to Board of Directors"}, {"id":140833206,"url":"https://finnhub.io/api/news?id=65759f7b20687911ba0211888e8514eff26a39a1955cc52a2bf51111456bf34a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"IDXX","summary":"ALC vs. IDXX: Which Stock Is the Better Value Option?","category":"company","datetime":1783438804,"headline":"ALC vs. IDXX: Which Stock Is the Better Value Option?"}, {"id":140829324,"url":"https://finnhub.io/api/news?id=670d24384e72cfda3d62fce924d33273b1ae6820242ec06bb1bc89f23377b55d","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249694010/image_2249694010.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"IDXX","summary":"IDEXX Laboratories (IDXX) is rated Hold, as its premium valuation (~38x 2026E EPS) already assumes strong recurring revenue and diagnostics growth.","category":"company","datetime":1783411123,"headline":"IDEXX Laboratories Does Not Need More Vet Visits--But It Needs More Tests Per Visit"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 4
recomputed_at_score true
sentiment_score_raw 1.2
source_article_count 38
discarded_article_count 27
sentimentPoints 6

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 4.6 5/110 92% 4.6
資金流 12.4 20/110 62% 12.4
市場環境 5.8 15/110 38.67% 5.8
催化劑 6 20/110 30% 6
風險管理 6.7 10/110 67% 6.7
技術信號 20.8 30/110 69.33% 20.8
情緒分析 6 10/110 60% 6

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 9/50
ret_5d 0.0558
max_score 50
max_total 50
raw_total 9
vcp_bonus 0
vol_ratio 0.9479
ret_points 8
vol_points 0
range_ratio 0.9054
volat_points 0
day_range_pct 0.0285
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 1
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.3

details

atrPct 3.2884
turnoverUsdM 377.2336
liquidityPoints 0.6
volatilityPoints 0.7
rrPoints 1.6

stopLevels

symbol US.IDXX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 551.1964

strength_details

ma_score 2
atr_score 1
rsi_score 3
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1.5
stop_loss_percent 6.6
take_profit_price 649.7575
target_multiplier 2.2
technical_strength 2.1
take_profit_percent 10.1
positionPoints 1.3
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.5357
stopLossPercent 6.5769
diversificationPoints 2

Calculation audit log

基本面分析總分: 4.6/5分
資金流分析總分: 12.4/20分
市場環境分析總分: 5.8/15分
催化劑分析: 6/20分
風險管理總分: 6.7/10分
技術信號分析總分: 20.8/30分
情緒分析: 6/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 100
atr
atr 19.4018
rule ATR / current price; lower volatility scores higher
score 4
atr_pct 3.29
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value 123.51
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.1755
kdj
d 57.93
j 57.51
k 57.79
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 弱流入
score 4
value 46.14
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 10
trend 強流入
value 7521679
recentSlope 400407.9
previousSlope -56180
rsi
value 60.52
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 537.9157
position SAR喺價下
distancePct 8.83
previousTrend 上升
ma50
value 559.2538
macd
macd 7.0229
trend 強烈看漲
signal 3.5013
histogram 3.5216
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 567.5782
position 連續5日>VWAP
consecutiveAbove 9
volume
rule Cursor_18.24 volume ratio
level 無力
ratio 0.97
score 4
avgVolume 656839
currentVolume 639379
derived
ma20 562.902
ma50 559.2538
prevClose 584.78
avgVolume10 734188
avgVolume20 656839
changePercent 0.89
avgVolumeForScore 656839
ma_cross
ma20 562.902
ma50 559.2538
rule Cursor_18.24 MA20/MA50 cross
cross 接近
score 6
prevMa20 561.332
prevMa50 558.598
spreadPct 0.65
isVolumeBreakout false
bollinger
lower 534.2895
upper 591.5145
position 上半部
rsi_short
value 70.73
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.97

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.288440677966102,
        "turnoverUsdM": 377.23361,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.6,
    "stopLevels": {
      "symbol": "US.IDXX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 551.1964,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 1,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.5,
      "stop_loss_percent": 6.6,
      "take_profit_price": 649.7575,
      "target_multiplier": 2.2,
      "technical_strength": 2.1,
      "take_profit_percent": 10.1
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.535682256285499,
    "stopLossPercent": 6.576881355932204,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 71.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 62.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 9
  },
  "market": {
    "ma20": 562.902,
    "ma50": 559.2538,
    "close": 590,
    "prevClose": 584.78,
    "avgVolume20": 656839,
    "volumeRatio": 0.97,
    "changePercent": 0.89
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 9,
    "details": {
      "ret_5d": 0.05583394874434422,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 9,
      "vcp_bonus": 0,
      "vol_ratio": 0.947909238489878,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 0.9054282250309906,
      "volat_points": 0,
      "day_range_pct": 0.0284999999999999,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 71.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 92,
        "contribution": 4.6
      },
      {
        "raw": 12.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 62,
        "contribution": 12.4
      },
      {
        "raw": 5.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 38.67,
        "contribution": 5.8
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 67,
        "contribution": 6.7
      },
      {
        "raw": 20.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 69.33,
        "contribution": 20.8
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 62.3,
    "details": [
      "基本面分析總分: 4.6/5分",
      "資金流分析總分: 12.4/20分",
      "市場環境分析總分: 5.8/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.7/10分",
      "技術信號分析總分: 20.8/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 4.6,
      "資金流": 12.4,
      "市場環境": 5.8,
      "情緒分析": 6,
      "技術信號": 20.8,
      "風險管理": 6.7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 377.23361,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.IDXX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 700.4619942500001,
                "ma50": 714.69519954,
                "name": "QQQ",
                "close": 714.62,
                "points": 1
              },
              "spy": {
                "ma20": 749.25550215,
                "ma50": 746.7324035600001,
                "name": "SPY",
                "close": 768.53003,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.288440677966102,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141137395,
                "url": "https://finnhub.io/api/news?id=508ecee4b431fd16e2434a6b8e6ab733a99c95454a2c88c6ea980ae36db4e0de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.",
                "category": "company",
                "datetime": 1786034702,
                "headline": "Here is Why Growth Investors Should Buy Idexx (IDXX) Now"
              },
              {
                "id": 141115049,
                "url": "https://finnhub.io/api/news?id=35666a9bb49c4defe08fd7f184a0fdaf5e5299135345edcdfa0af2ae31070cf5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories Inc (IDXX) delivers 10% revenue growth and raises full-year EPS outlook, driven by innovation and international expansion despite soft US clinical visits.",
                "category": "company",
                "datetime": 1785877482,
                "headline": "IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ..."
              },
              {
                "id": 141111998,
                "url": "https://finnhub.io/api/news?id=83e1f9fb12f611558ef734564b6fd42e2870b2d019da6072c3946cd0eb8eb275",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.",
                "category": "company",
                "datetime": 1785858600,
                "headline": "IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market"
              },
              {
                "id": 141110272,
                "url": "https://finnhub.io/api/news?id=df4fe0d5649e29085ff8f5db2463bf2ba5929763aa3afc4e378245e55119c9f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
                "category": "company",
                "datetime": 1785850203,
                "headline": "Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say"
              },
              {
                "id": 141110757,
                "url": "https://finnhub.io/api/news?id=10d15d5066a10226b8b4f2707dca3e330f79462337105e2a790aa74f16daa661",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "IDXX",
                "summary": "IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDTCompany ParticipantsAndrew Emerson - Executive VP, CFO &...",
                "category": "company",
                "datetime": 1785847203,
                "headline": "IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141108859,
                "url": "https://finnhub.io/api/news?id=e64abee23339868ce4d7fdeb84d6e5cab92de3c3011238b7cc317ca976d4a62e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Idexx (IDXX) delivered earnings and revenue surprises of +8.10% and +1.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785843602,
                "headline": "Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 141107590,
                "url": "https://finnhub.io/api/news?id=0635386d343671799513e1a251b0499c00d73d358e70668a88cd5cbd3cab1c9d",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp",
                "source": "ChartMill",
                "related": "IDXX",
                "summary": "IDEXX Laboratories Q2 EPS beats estimates, revenue in line; raises full-year organic growth and margin outlook, shares rise 3.7% premarket.",
                "category": "company",
                "datetime": 1785843538,
                "headline": "IDEXX Laboratories (NASDAQ:IDXX) Shares Rise on Q2 Earnings Beat and Improved Outlook"
              },
              {
                "id": 141107199,
                "url": "https://finnhub.io/api/news?id=3fa4a1c8b8141c2ebb6d273173d2541b08b83b8dc8869f4c6e1e5382bd4bf23a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Evaluate the expected performance of Idexx (IDXX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
                "category": "company",
                "datetime": 1785503704,
                "headline": "Insights Into Idexx (IDXX) Q2: Wall Street Projections for Key Metrics"
              }
            ],
            "raw_source": [
              {
                "id": 141137395,
                "url": "https://finnhub.io/api/news?id=508ecee4b431fd16e2434a6b8e6ab733a99c95454a2c88c6ea980ae36db4e0de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.",
                "category": "company",
                "datetime": 1786034702,
                "headline": "Here is Why Growth Investors Should Buy Idexx (IDXX) Now"
              },
              {
                "id": 141127989,
                "url": "https://finnhub.io/api/news?id=9ea47d2df35b0a3000496d548d8eb669c74f4e1765fc3d2d1d09adc207567acf",
                "image": "",
                "source": "Benzinga",
                "related": "IDXX",
                "summary": "UBS  analyst Andrea Alfonso   maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $620 to $670.",
                "category": "company",
                "datetime": 1785947269,
                "headline": "UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670"
              },
              {
                "id": 141127990,
                "url": "https://finnhub.io/api/news?id=2d8aeb3471d09af00fde5776b03b792f1a86254ca7c38f585d9ec65ec7c33492",
                "image": "",
                "source": "Benzinga",
                "related": "IDXX",
                "summary": "Citigroup  analyst Daniel Grosslight   maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $650 to $670.",
                "category": "company",
                "datetime": 1785941909,
                "headline": "Citigroup Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670"
              },
              {
                "id": 141116574,
                "url": "https://finnhub.io/api/news?id=1609d532f3454898719b288eb650c0d0015b7435f5d672dd36fb565cb9b5e16b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Moby summary of IDEXX Laboratories, Inc.'s Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785881732,
                "headline": "IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141115049,
                "url": "https://finnhub.io/api/news?id=35666a9bb49c4defe08fd7f184a0fdaf5e5299135345edcdfa0af2ae31070cf5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories Inc (IDXX) delivers 10% revenue growth and raises full-year EPS outlook, driven by innovation and international expansion despite soft US clinical visits.",
                "category": "company",
                "datetime": 1785877482,
                "headline": "IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ..."
              },
              {
                "id": 141111997,
                "url": "https://finnhub.io/api/news?id=879ec92aa94d2ff93e91544e65d404a03f30dee6a7ec215f202c64407575e671",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing s",
                "category": "company",
                "datetime": 1785859468,
                "headline": "IDEXX Laboratories Q2 Earnings Call Highlights"
              },
              {
                "id": 141111998,
                "url": "https://finnhub.io/api/news?id=83e1f9fb12f611558ef734564b6fd42e2870b2d019da6072c3946cd0eb8eb275",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.",
                "category": "company",
                "datetime": 1785858600,
                "headline": "IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market"
              },
              {
                "id": 141110272,
                "url": "https://finnhub.io/api/news?id=df4fe0d5649e29085ff8f5db2463bf2ba5929763aa3afc4e378245e55119c9f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
                "category": "company",
                "datetime": 1785850203,
                "headline": "Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say"
              },
              {
                "id": 141108599,
                "url": "https://finnhub.io/api/news?id=9e1fcc0db18c7b217918b53e92794d7424423d9adeeac84c7117497a2224b4eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively trad",
                "category": "company",
                "datetime": 1785849279,
                "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Strait of Hormuz Re-Opening Hopes"
              },
              {
                "id": 141110757,
                "url": "https://finnhub.io/api/news?id=10d15d5066a10226b8b4f2707dca3e330f79462337105e2a790aa74f16daa661",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "IDXX",
                "summary": "IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDTCompany ParticipantsAndrew Emerson - Executive VP, CFO &...",
                "category": "company",
                "datetime": 1785847203,
                "headline": "IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141108584,
                "url": "https://finnhub.io/api/news?id=be360b5ab3037f6e5b84023ad5260321d5a02ff6bbf4cb5616b3d33c11e350aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "The 180 MW Phase II portion of the Millers Branch Solar Facility in Haskell County, Texas has achieved commercial operation. The capacity was contracted through Sustainability Roundtable, Inc's Net Zero Consortium for Buyers (NZCB) by Cisco, Juniper Networks (now part of Hewlett Packard Enterprise), Bio-Rad Laboratories, Cadence Design Systems, IDEXX Laboratories, Inc., PTC, and a large healthcare company, which signed an aggregated virtual power purchase agreement (VPPA) with Southern Power Com",
                "category": "company",
                "datetime": 1785846600,
                "headline": "SR Inc Net Zero Consortium for Buyers: Seven-Buyer Aggregation for 180 MW of Millers Branch Solar Now Online"
              },
              {
                "id": 141108858,
                "url": "https://finnhub.io/api/news?id=7bba2e26b45919de61a82ea0a88d1559c686252b35de4654cfef676d2bac86ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories Inc. (NASDAQ:IDXX) shares rose nearly 4% in pre-market trading after the veterinary diagnostics company reported second-quarter 2026 results that exceeded Wall Street expectations and increased its full-year earnings guidance.",
                "category": "company",
                "datetime": 1785845734,
                "headline": "IDEXX Laboratories Shares Climb After Earnings Beat and Improved Full-Year Outlook"
              },
              {
                "id": 141108859,
                "url": "https://finnhub.io/api/news?id=e64abee23339868ce4d7fdeb84d6e5cab92de3c3011238b7cc317ca976d4a62e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Idexx (IDXX) delivered earnings and revenue surprises of +8.10% and +1.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785843602,
                "headline": "Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 141110524,
                "url": "https://finnhub.io/api/news?id=d507772958f2a8a819a520e890396c431b45d6cadd3662cbe5fc9050696b43b5",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/04/Saint-Petersburg--Russia---June-25--2019.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "IDXX",
                "summary": "IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates.",
                "category": "company",
                "datetime": 1785843581,
                "headline": "Why Is IDEXX Laboratories Stock Gaining Tuesday?"
              },
              {
                "id": 141107590,
                "url": "https://finnhub.io/api/news?id=0635386d343671799513e1a251b0499c00d73d358e70668a88cd5cbd3cab1c9d",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp",
                "source": "ChartMill",
                "related": "IDXX",
                "summary": "IDEXX Laboratories Q2 EPS beats estimates, revenue in line; raises full-year organic growth and margin outlook, shares rise 3.7% premarket.",
                "category": "company",
                "datetime": 1785843538,
                "headline": "IDEXX Laboratories (NASDAQ:IDXX) Shares Rise on Q2 Earnings Beat and Improved Outlook"
              },
              {
                "id": 141107879,
                "url": "https://finnhub.io/api/news?id=ed480ae00c1539e1892006ea492210346c62f6b9a8e81f21bd2104a0bb3d9830",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "WESTBROOK, Maine, August 04, 2026--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results.",
                "category": "company",
                "datetime": 1785839400,
                "headline": "IDEXX Laboratories Announces Second Quarter Results"
              },
              {
                "id": 141110525,
                "url": "https://finnhub.io/api/news?id=ad9101e6b258fb9df0687c4fd5bfb4b57c4560459a911f54eec7154cb67c7bc3",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "IDXX",
                "summary": "IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below.\nThis transcript is brought to you by",
                "category": "company",
                "datetime": 1785836133,
                "headline": "IDEXX Laboratories Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141110526,
                "url": "https://finnhub.io/api/news?id=1ad20007053f9b0a59617bdf1d05c449115862bcff863f1dc1744b563b72aed6",
                "image": "",
                "source": "Benzinga",
                "related": "IDXX",
                "summary": "IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to $4.700 billion-$4.745",
                "category": "company",
                "datetime": 1785825085,
                "headline": "IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est"
              },
              {
                "id": 141110527,
                "url": "https://finnhub.io/api/news?id=62ef9305ab6ee3d802c53446aecac4ad338233beefe19782bf2a33317cea31b0",
                "image": "",
                "source": "Benzinga",
                "related": "IDXX",
                "summary": "IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $4.27 per share which beat the analyst consensus estimate of $3.96 by 7.83 percent. This is a 17.63 percent increase over earnings of $3.63 per share from",
                "category": "company",
                "datetime": 1785825041,
                "headline": "IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate"
              },
              {
                "id": 141107199,
                "url": "https://finnhub.io/api/news?id=3fa4a1c8b8141c2ebb6d273173d2541b08b83b8dc8869f4c6e1e5382bd4bf23a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Evaluate the expected performance of Idexx (IDXX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
                "category": "company",
                "datetime": 1785503704,
                "headline": "Insights Into Idexx (IDXX) Q2: Wall Street Projections for Key Metrics"
              },
              {
                "id": 141064002,
                "url": "https://finnhub.io/api/news?id=78a4d1603a77e856648e6b81ca7e57bd4535b29f68a48b51a09468d5d73cd6f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Corporate responsibility report puts IDEXX Laboratories (IDXX) in focus IDEXX Laboratories (IDXX) recently released its 2025 Corporate Responsibility Report, drawing attention to the stock as investors assess how the company’s plans for pet diagnostics, employees, and sustainability fit into its long term outlook. See our latest analysis for IDEXX Laboratories. The recent 6.3% 30 day share price return contrasts with IDEXX Laboratories’ share price being down 15.0% year to date, while the 3...",
                "category": "company",
                "datetime": 1785402557,
                "headline": "Is IDEXX Laboratories (IDXX) Fairly Valued After Its 2025 Corporate Responsibility Report?"
              },
              {
                "id": 141044045,
                "url": "https://finnhub.io/api/news?id=b1da3556d2d574e870a83df23713073e6a9208be636af8ce22b2f1ae4863e556",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories (NASDAQ:IDXX) released its 2025 Corporate Responsibility Report, outlining progress across innovation, workforce development, and environmental initiatives that support the company’s long-term growth strategy. Key Investor TakeawaysIDEXX published its 2025 Corporate Responsibility Report, highlighting advances in innovation, employee development, and sustainability.",
                "category": "company",
                "datetime": 1785247577,
                "headline": "IDEXX Releases 2025 Corporate Responsibility Report Highlighting Innovation and Sustainability Progress"
              },
              {
                "id": 141041871,
                "url": "https://finnhub.io/api/news?id=b2b39e026a9f2b1d33a3361976ee4c82a3961bb0b961ec4983de41dc2a6ac5ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "WESTBROOK, Maine, July 28, 2026--IDEXX releases 2025 Corporate Responsibility Report highlighting progress against its goals and commitments.",
                "category": "company",
                "datetime": 1785236400,
                "headline": "IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals"
              },
              {
                "id": 141035335,
                "url": "https://finnhub.io/api/news?id=5955aa767bb5270fec33b69b0c4c5c70daa999824702bad4a7ec9365aa0a90a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Elanco Animal Health (ELAN) seems \"best-positioned name\" into the Q2 print, with IDEXX Laboratories",
                "category": "company",
                "datetime": 1785172169,
                "headline": "Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says"
              },
              {
                "id": 141037509,
                "url": "https://finnhub.io/api/news?id=24398a18d386daee23962fa28a40282f669fdac74cb88dc12bc606fba6db6311",
                "image": "",
                "source": "Benzinga",
                "related": "IDXX",
                "summary": "UBS  analyst Andrea Alfonso   maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $640 to $620.",
                "category": "company",
                "datetime": 1785161332,
                "headline": "UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $620"
              },
              {
                "id": 141034163,
                "url": "https://finnhub.io/api/news?id=7dfbcbf4ac51d4c89fb1a320c9a619e05c9b4623934b10d1328c714f4f1f1c4e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDXX Laboratories heads into Q2 earnings with revenue and EPS growth expected, led by CAG diagnostics, VetLab gains and expanding software adoption.",
                "category": "company",
                "datetime": 1785157860,
                "headline": "Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings"
              },
              {
                "id": 141032284,
                "url": "https://finnhub.io/api/news?id=7dd4d57acaf274b6e3e346093d3355cfad56eb8eb2422b863e70ef234edf607a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Composite “. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]",
                "category": "company",
                "datetime": 1785153600,
                "headline": "IDEXX Laboratories (IDXX) Looks Attractive on Recurring Revenue and High Customer Retention"
              },
              {
                "id": 140952943,
                "url": "https://finnhub.io/api/news?id=d9e8b333e8a462d43b0b84e3d28b24f605b4595d4a56df8c849f9112e8b797fe",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1056792912/image_1056792912.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "IDXX",
                "summary": "Ron Baron’s BAMCO 13F update: $33.13B portfolio with Tesla top stake (13.39%), major buys/sells, and rebalancing moves—read more now.",
                "category": "company",
                "datetime": 1784468597,
                "headline": "Tracking Ron Baron's BAMCO Portfolio - Q1 2026 Update"
              },
              {
                "id": 140944614,
                "url": "https://finnhub.io/api/news?id=307e412a7579741a0fddefc62643bfcb67d4a3ac5c44974b5af6ec260e2e65c5",
                "image": "https://image.cnbcfm.com/api/v1/image/108335808-1784189865798-gettyimages-168597290-000023514379_Unapproved.jpeg?v=1784189915&w=1920&h=1080",
                "source": "CNBC",
                "related": "IDXX",
                "summary": "Startups are testing GLP-1 treatments for overweight cats while pet-food giants are leaning into longevity products as owners spend more on animal health.",
                "category": "company",
                "datetime": 1784336402,
                "headline": "Fat cat? Weight-loss drugs may be coming for your overweight pet"
              },
              {
                "id": 140912442,
                "url": "https://finnhub.io/api/news?id=d213a7bc45e61de090c471914ad23104be342b21d7fdfd1d103000c412ff81b2",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "IDXX",
                "summary": "Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1784142301,
                "headline": "Which S&P500 stocks are moving on Wednesday?"
              },
              {
                "id": 140910529,
                "url": "https://finnhub.io/api/news?id=17e09f5f6e4cea4cc429b9c6762b4a6aea15f224d1fcabc885c31bb22bc18f3f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "IDXX",
                "summary": "Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1784133300,
                "headline": "These S&P500 stocks are moving in today's session"
              },
              {
                "id": 140909866,
                "url": "https://finnhub.io/api/news?id=1f4f929efb2a32e0b32eb27e903fc3db2f1bf483f90bbb2e518c77ea8ed7d823",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "As data centers strain water systems, FIW, PHO, and CGW offer investors ETF-based access to water utilities, infrastructure, and equipment firms, each with distinct fees and concentration.",
                "category": "company",
                "datetime": 1784040300,
                "headline": "These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending"
              },
              {
                "id": 140897029,
                "url": "https://finnhub.io/api/news?id=de059f2a8fa06678f5cc3ec3105d8f2309e7ab75251bb23b2ed80e39fd10c688",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "ISRG, IDXX and ALC are three AI-driven medical device laggards with strong business momentum and improving earnings estimates for a potential 2H rebound.",
                "category": "company",
                "datetime": 1784029020,
                "headline": "Buy 3 AI-Led Medical Devices Laggards of 1H Set to Gather Pace in 2H"
              },
              {
                "id": 140891433,
                "url": "https://finnhub.io/api/news?id=0d1b45131aa89d56944dfc353489756ba4f4b458a3280ab510525755ce221788",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "IDEXX Laboratories will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.",
                "category": "company",
                "datetime": 1783951251,
                "headline": "IDEXX Laboratories Earnings Preview: What to Expect"
              },
              {
                "id": 140852386,
                "url": "https://finnhub.io/api/news?id=73d2e925c78520c16003ce9b14439312d62e875d68f28251208e2f9c1544a395",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.",
                "category": "company",
                "datetime": 1783607280,
                "headline": "Illumina Stock Gains 43.7% in 2026: What's Powering the Rally?"
              },
              {
                "id": 140851088,
                "url": "https://finnhub.io/api/news?id=9410d1b059637b5b9b027f896f96c5969d2fb0cedd319521c369aa322f8e57b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "National Veterinary Associates (NVA), a leading pet healthcare services company, today announced the appointment of Laura Tortorella, Chief Executive Officer of AccentCare, and Tina Hunt, PhD, former Executive Vice President of IDEXX Laboratories, to its Board, effective immediately.",
                "category": "company",
                "datetime": 1783598400,
                "headline": "National Veterinary Associates Welcomes Laura Tortorella and Tina Hunt, PhD, to Board of Directors"
              },
              {
                "id": 140833206,
                "url": "https://finnhub.io/api/news?id=65759f7b20687911ba0211888e8514eff26a39a1955cc52a2bf51111456bf34a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "IDXX",
                "summary": "ALC vs. IDXX: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1783438804,
                "headline": "ALC vs. IDXX: Which Stock Is the Better Value Option?"
              },
              {
                "id": 140829324,
                "url": "https://finnhub.io/api/news?id=670d24384e72cfda3d62fce924d33273b1ae6820242ec06bb1bc89f23377b55d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249694010/image_2249694010.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "IDXX",
                "summary": "IDEXX Laboratories (IDXX) is rated Hold, as its premium valuation (~38x 2026E EPS) already assumes strong recurring revenue and diagnostics growth.",
                "category": "company",
                "datetime": 1783411123,
                "headline": "IDEXX Laboratories Does Not Need More Vet Visits--But It Needs More Tests Per Visit"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 38,
            "discarded_article_count": 27
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.8,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50;升放量(近10日2日);Ready=N;Confirm=Y",
            "vcp_metrics": {
              "up_days": 7,
              "vol_ref": 697903.3333333334,
              "down_days": 2,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 716190,
              "avg_vol_20": 674515,
              "avg_vol_30": 697903.3333333334,
              "range_pct_10": 0.15218649152542374,
              "range_pct_20": 0.15218649152542374,
              "range_pct_30": 0.17898310169491535,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0262022916258697,
              "dist_to_20d_high": 0.05471444189010847,
              "down_shrink_days": 1,
              "breakout_level_20d": 624.15002,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.8502841334420072
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.288440677966102,
              "turnoverUsdM": 377.23361,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.6,
          "stopLevels": {
            "symbol": "US.IDXX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 551.1964,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 1,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.5,
            "stop_loss_percent": 6.6,
            "take_profit_price": 649.7575,
            "target_multiplier": 2.2,
            "technical_strength": 2.1,
            "take_profit_percent": 10.1
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.535682256285499,
          "stopLossPercent": 6.576881355932204,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.IDXX",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 19.4018,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.29
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 123.51
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1755
    },
    "kdj": {
      "d": 57.93,
      "j": 57.51,
      "k": 57.79,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 46.14
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 7521679,
      "recentSlope": 400407.9,
      "previousSlope": -56180
    },
    "rsi": 60.52,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 537.9157,
      "position": "SAR喺價下",
      "distancePct": 8.83,
      "previousTrend": "上升"
    },
    "ma50": 559.2538,
    "macd": {
      "macd": 7.022893728374356,
      "trend": "強烈看漲",
      "signal": 3.501263798641668,
      "histogram": 3.521629929732688
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 567.5782,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 9
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.97,
      "score": 4,
      "avgVolume": 656839,
      "currentVolume": 639379
    },
    "derived": {
      "ma20": 562.902,
      "ma50": 559.2538,
      "prevClose": 584.78,
      "avgVolume10": 734188,
      "avgVolume20": 656839,
      "changePercent": 0.89,
      "avgVolumeForScore": 656839
    },
    "ma_cross": {
      "ma20": 562.902,
      "ma50": 559.2538,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 561.332,
      "prevMa50": 558.598,
      "spreadPct": 0.65,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 534.2895,
      "upper": 591.5145,
      "position": "上半部"
    },
    "rsi_short": 70.73,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.97
    }
  }
}

Raw metrics JSON

{
  "close": 590,
  "volume": 639379,
  "changePercent": 0.89
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.